Microbiotica reported positive Phase Ib results for MB‑310, an oral live biotherapeutic for ulcerative colitis: 12 of 19 treated patients achieved clinical remission versus three of 10 on placebo. Responders sustained remission and complete resolution of rectal bleeding during three months of follow‑up, with accompanying histological improvements. The company highlighted the safety profile and durability seen in the follow‑up window as reasons to advance development. The data support MB‑310 as a clinically active oral microbiome therapy candidate and strengthen the case for larger randomized studies to confirm efficacy and durability in inflammatory bowel disease.